MISTIE INTRACEREBRAL HEMORRHAGE TRIAL

Does faster clot removal in ICH give better patient outcomes?

115 Sites to Qualify:
115
90 Sites to Activate:
77
500 Participants to Enroll:
506

Next Steps for Qualified MISTIE-III Sites

Next Steps for Qualified MISTIE-III Sites

You've submitted your Site Suitability Assessment Survey (SASS), completed the team feasibility interview, and have been accepted into the MISTIE-III consortium. Congratulations! Now what are the next steps? Your "Startup Sherpa" (a/k/a your site manager) will guide you on this next step "up the mountain" but here's a brief summary of the steps and some important links.

You must book your hotel room no later than 18-October, so be sure to read all the details below!

Continue reading
5012 Hits

BIOS Summer Student Projects Provide New Data About MISTIE Surgical Task

BIOS Summer Student Projects Provide New Data About MISTIE Surgical Task

As the summer comes to an end and we begin training for MISTIE III, there is no better time to reflect on what we learned from MISTIE II, and who better to help us with that than summer interns! This year we were lucky to have three wonderful interns (pictured below with Dr. Hanley from left to right): Qian Qian Liu from University of Maryland Medical School, Shane Thorp from Gettysburg College, and Ryan Fisico from Johns Hopkins University. 

Continue reading
3817 Hits

On the Road to MISTIE III - EDC Form Design Considerations

The June MISTIE III webinar focused on one of the most important tasks in preparing for the launch of the trial this fall -- designing the electronic data capture (EDC) system forms.  Steve Mayo gave a presentation reviewing the form designs from the prior MISTIE and CLEAR trials and the considerations that are currently going into designing the online case report forms for MISTIE III.

Coordinators are invited to get involved in these early planning efforts and provide suggests for how to optimize and simplify data collection for this new trial.

 

4737 Hits

MISTIE-II 365-Day Results Presented at 2013 International Stroke Conference

b2ap3_thumbnail_Dan-ISC-Photo.jpg

Dr. Daniel Hanley, co-principal investigator for the MISTIE clinical trial, was a featured speaker this week at the 2013 International Stroke conference (ISC) in Honolulu as he presented 365-day results from this phase-II clinical trial. MISTIE is an acronym for Minimally Invasive Surgery + rt-PA for Intracerebral Hemorrhage (ICH) Evacuation. ICH is a type of stroke caused by bleeding within the brain, often the result of uncontrolled hypertension. It is also referred to as cerebral stroke or hemorrhagic stroke.

This recently-completed proof-of-concept trial evaluated the use of tPA (a thrombolytic or clot-busting drug) delivered via a catheter placed under CT (a series of x-ray images) guidance. Data from the 123 patients enrolled across 26 medical centers provides ground-breaking evidence, which now needs to be verified in a larger phase-III trial, that this technique offers future promise for reducing the high rate of death and serious disability in ICH patients. Preliminary results were presented at last year's conference. Now that study participants have reached the one-year mark, the final results are even more encouraging. A summary of these results have been published on the American Stroke Society's ISC website -- scroll to the bottom to see Dr. Hanley's late-breaking presentation materials.

Continue reading
8518 Hits

Aloha! BIOS at the International Stroke Conference!

b2ap3_thumbnail_hotel-hero.png

Aloha Friends! In just a few short days, we will be in sunny Honolulu at the International Stroke Conference. During the conference this year, we have many exciting programs and presentations about the findings from MISTIE II and future plans for MISTIE III. Continue reading for details on all events. We hope to see you there!

Continue reading
4018 Hits

Brain Injury Outcomes

Johns Hopkins University
1550 Orleans Street
CRB-II, 3M50 South
Baltimore, MD 21231 USA
Office:   (410) 614-6996
Fax: (410) 502-7869
 
24-Hr: (410) 736-1368